Ticker

Additional financing from a world-class investor syndicate further strengthens the combined company's balance sheet to accelerate development of AVR-001 Private placement and the previously announced concurrent private placement are expected to fully fund Avere's operating plan into 2029 SAN FRANCISCO, Aug. 10, 2026 /PRNewswire/ -- Avere Therapeutics, Inc. ("Avere" or the "Company"), a privately-held biotechnology…

NextCure, Inc. (NASDAQ: NXTC - Get Free Report) was the target of a large increase in short interest in the month of July. As of July 15th, there was short interest totaling 1,323,834 shares, an increase of 734.7% from the June 30th total of 158,592 shares. Approximately 41.6% of the shares of the stock are short

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws

NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--VEEE, NXTC, TCBK, and FHB PR Newswire